Clinical trial
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00099229 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00099229 |
|---|---|
| Title | Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Tolerability of Licarbazepine 1000-2000mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Over 3 Weeks |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Licarbazepine |
| Enrollment | 320 |
| Start date | Nov 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Dec 10, 2004 |
| Last update posted | Feb 23, 2017 |
| Countries | France, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: